Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

New approval for Lilly's Humalog

Oct. 11, 1996

UCSF scientists discover protein involved in insulin resistance

Oct. 11, 1996

Novel, highly potent antihyperglycemic agents from SmithKline Beecham

Oct. 11, 1996

Nissan Chem. claims hypoglycemic agents for diabetes

Oct. 11, 1996

Progress in development of NPS's R-568

Oct. 11, 1996

Future metabolic agents in the Yamanouchi pipeline

Oct. 11, 1996

ProScript and Roche to develop compounds for cachexia

Oct. 11, 1996

Appetite-suppressing effects of urocortin

Oct. 11, 1996

Pravastatin continues to demonstrate clinical utility in various patient groups

Oct. 11, 1996

Generic cholestyramine cleared by FDA

Oct. 11, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.